MetaCap

BridgeBio Oncology Therapeutics (BBOT) vs InflaRx N.V. (IFRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

InflaRx N.V. (IFRX) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 11.9% versus a loss of 85.4%. InflaRx N.V. is the larger company by market cap ($153.3 million vs $145.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBOT-85.39%IFRX-11.86%
+143%+23%-96%
Nov 21, 20251 yearNov 20, 2026
BBOT-82.24%IFRX-31.58%
+80%-5%-90%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBOT versus IFRX key metrics
MetricBBOTIFRX
Share price$1.81$1.04
Market cap$145.25M$153.26M
1-day change-2.69%-4.59%
YTD return-85.54%+2.97%
1-year return-85.39%-11.86%
5-year return—-79.53%
P/E ratio (TTM)3.42—
EPS (TTM)$0.53$-0.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-134.04M—
52-week high$14.87$2.95
52-week low$1.79$0.798
Distance from 52-week high-87.83%-64.73%
Analyst consensusstrong_buynone
Avg. price target upside+1060.22%+696.15%
Average volume631.56K868.66K
Shares outstanding80.25M147.37M
Employees9265
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IFRX has outperformed BBOT by 73.5 percentage points over the past year.

About BridgeBio Oncology Therapeutics

BBOT stock →

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.

Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees

About InflaRx N.V.

IFRX stock →

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

BBOT vs IFRX FAQ

Which is bigger, BridgeBio Oncology Therapeutics or InflaRx N.V.?

InflaRx N.V. (IFRX) is larger, with a market capitalization of $153.26M compared with $145.25M for BridgeBio Oncology Therapeutics (BBOT).

Which stock has performed better over the past year, BBOT or IFRX?

IFRX returned -11.86% over the past 12 months, compared with -85.39% for BBOT (price return, excluding dividends). Past performance does not predict future results.

Are BridgeBio Oncology Therapeutics and InflaRx N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons